Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
Summary
Crinetics Pharmaceuticals, Inc. announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will present a corporate update at the 43rd annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will highlight the company's key priorities and anticipated milestones for 2025, including advancing its drug candidates for acromegaly, congenital adrenal hyperplasia, and other endocrine disorders. A corporate slide presentation has been posted on the company's website.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement